Feasibility of an Online Modeled Exposure in Spider Fearful Individuals (OMEX)

September 27, 2025 updated by: Philipps University Marburg

Group Exposure Treatment: Feasibility of an Online Modeled Exposure in Spider Fearful Individuals

The effectiveness of an optimized group exposure treatment is investigated in spider-fearful individuals. Participants will undergo an optimized standardized exposure treatment. After receiving information about the treatment and the phobic stimulus (spider) through a psychoeducation video, participants will observe an exposure treatment of another fearful person, either live or by watching a movie of an exposure treatment online. Subsequently, participants will undergo a live in vivo exposure treatment conducted in a group setting. The effectiveness of the treatment is measured by symptom improvement according to online behavioral avoidance tests and subjective ratings immediately after training and one week later.

Study Overview

Detailed Description

The treatment of various anxiety disorders often involves exposure therapy. However, a considerable number of patients do not benefit or experience a resurgence of anxiety following successful treatment. Vicarious safety learning (i.e., modeled exposure) presents a promising avenue to improve therapeutic outcome. Previous evidence indicates that vicarious safety learning can diminish previously acquired fear associations, thereby reducing behavioral avoidance. While single-session interventions have implemented modeled exposure, specific mechanisms of observational learning have not been extensively investigated. Due to high dropout rates in specific phobias, modeled exposure could be utilized as an additional treatment method, potentially yielding better outcomes trough additional learning experience.

This study aims to investigate the applicability of observational learning and its sustainability through mental retrieval cues. Specifically, the study is going to assess the feasibility of modeled exposure conveyed either live or online via video, offering a practical approach within a stepped-care framework. The modeled exposure treatment will be followed by a group exposure treatment to assess the influence of modeled exposure in spider-fearful individuals.

Physically healthy spider-fearful individuals will be either treated with an online or live modeled standardized exposure followed by a group exposure treatment. Half of the participants will receive a mental retrieval cue before the group exposure treatment one day after the modeled exposure treatment. The research aims to determine if long-term reduction of spider fear is achievable through online modeled exposure via video compared to in-person modeled exposure.

Study Type

Interventional

Enrollment (Actual)

78

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hesse
      • Marburg, Hesse, Germany, 35037
        • Philipps-University Marburg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- Elevated score on Spider Phobia Questionnaire (SPQ) >= 17

Exclusion Criteria:

  • Severe allergies to bees/spiders/insects
  • Current psychiatric/psychotherapeutic treatment
  • Past psychotherapeutic/psychiatric treatment due to anxiety problems
  • Current or past psychotic symptoms
  • Current suicidal intent
  • Experience with exposure-based treatment
  • Current psychopharmacological medication
  • Severe respiratory, neurological or cardiovascular diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: online modeled exposure + mental retrieval cue group exposure
online modeled exposure training followed by group exposure training, including mental retrieval cue with five standardized exposure steps
Participants will watch a short psychoeducation video online. This will be followed by a modeled exposure online. In this modeled exposure participants watch a film of an exposure treatment (about 45min) conducted with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
Before the group exposure, participants are asked to remember the modeled exposure they had observed the day before. Therefore, the participants are asked to recall the location where they have been during the modeled exposure and the reaction of the patient during the exposure (e.g., fear decline).
Active Comparator: live modeled exposure + mental retrieval cue group exposure
live modeled exposure training followed by group exposure training, including mental retrieval cue with five standardized exposure steps
Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
Before the group exposure, participants are asked to remember the modeled exposure they had observed the day before. Therefore, the participants are asked to recall the location where they have been during the modeled exposure and the reaction of the patient during the exposure (e.g., fear decline).
Participants will watch a short psychoeducation video. This will be followed by a live modeled exposure. In this modeled exposure participants watch an exposure treatment (about 45min) conducted live with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
Active Comparator: online modeled exposure + standardized group exposure
online modeled exposure training followed by group exposure training with five standardized exposure steps
Participants will watch a short psychoeducation video online. This will be followed by a modeled exposure online. In this modeled exposure participants watch a film of an exposure treatment (about 45min) conducted with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
Active Comparator: live modeled exposure + standardized group exposure
live modeled exposure training followed by group exposure training with five standardized exposure steps
Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
Participants will watch a short psychoeducation video. This will be followed by a live modeled exposure. In this modeled exposure participants watch an exposure treatment (about 45min) conducted live with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spider Phobia Questionnaire (SPQ)
Time Frame: Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure - post treatment 2)
31-Item true/false questionnaire assessing symptoms of arachnophobia. Scores range from 0 to 31, with greater scores representing greater subjective fear of spiders, where lower scores reflect low subjective fear of spiders
Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure - post treatment 2)
Change in avoidance behavior (online virtual Behavioral Approach Task, vBATon)
Time Frame: Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure - post treatment 2)
Scores range from 0 ("participant refuses entering the room with the spider") to 12 ("participant holds the spider for at least 20 seconds")
Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure - post treatment 2)
Change in spider fear: Spider Anxiety Questionnaire (FSQ/SAF)
Time Frame: Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure - post treatment 2)
14-item questionnaire on a 7-point Likert-Scale (0 = "I don´t agree at all"; 6 = "I completely agree") to assess symptoms of arachnophobia. Total score can range from 0 to 98 Greater scores representing worse symptom severity of arachnophobia
Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure - post treatment 2)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in spider phobia belief questionnaire (SBQ)
Time Frame: Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure -- post treatment 2)
Assessment of spider phobia dysfunctional beliefs; 48 items on a scale from 0% ("no approval") to 100% ("full approval"); higher scores indicate more dysfunctional beliefs about the danger of spiders and own coping abilities regarding spiders
Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure -- post treatment 2)
Change in Spider Anxiety Screening (SAS)
Time Frame: Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure- post treatment 2)
Assessment of the four criteria for specific phobia (DSM-IV) with 4 items on a scale from 0 ("does not apply at all") to 6 ("fully applies"), Total score range: 0 to 24, higher scores indicating worse severity of symptoms of arachnophobia
Change from baseline to immediately post treatment 1 (after modeled exposure), immediately post treatment 2 (group exposure) and follow-up (7 days after group exposure- post treatment 2)
Global success rating (GSR)
Time Frame: Change from immediately post treatment 1 (after modeled exposure) to immediately post-treatment 2 (after group exposure) and follow-up (7 days after group exposure- post treatment 2)
Self-report measure of subjective state changes on a 7-likert scale from 1 ("much worse") to 7 ("much better")
Change from immediately post treatment 1 (after modeled exposure) to immediately post-treatment 2 (after group exposure) and follow-up (7 days after group exposure- post treatment 2)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety Sensitivity (ASI-3)
Time Frame: baseline
Self-report measure of anxiety-related body symptoms (i.e. anxiety sensitivity) with 18 items on a scale from 0 ("does not apply at all") to 4 ("fully applies"). Total score can range from 0 to 72; higher scores indicate worse anxiety sensitivity
baseline
Depression, Anxiety and Stress Scale (DASS)
Time Frame: baseline
Self-report measure of main symptoms of depression, anxiety, and stress, 21 items on a 4-point severity/frequency scale from 0 ("didn´t apply to me at all") to 4 ("applied very much to me, or most of the time"). Total score can range from 0 to 84, higher scores indicate higher symptom severity
baseline
Group Entitativity Measure-Group Therapy (GEM-GP)
Time Frame: immediately post-treatment 2 (after group exposure)
Single item visual analogue scale to measure group cohesion, scale can range from 1 to 6, higher scores indicate higher group cohesion
immediately post-treatment 2 (after group exposure)
Group Climate Questionnaire (GCQ-S)
Time Frame: immediately post-treatment 2 (after group exposure)
Self-report measure assessing perception of group atmosphere on 12 items rated on a 7-point Likert-scale (0 = "not at all" to 6 = "very much/extremely")
immediately post-treatment 2 (after group exposure)
Muenster Epistemic Trustworthiness Inventory (METI)
Time Frame: Change from immediately post treatment 1 (after modeled exposure) to immediately post-treatment 2 (after group exposure)
Self-report measure of epistemic trustworthiness, consisting of 14 antonyms on a 7-point scale, higher scales indicate higher epistemic trust
Change from immediately post treatment 1 (after modeled exposure) to immediately post-treatment 2 (after group exposure)
Intolerance of uncertainty (IUS-12)
Time Frame: baseline
Self-report measure to assess uncertainty intolerance with 12 items on a 5-point Likert-scale from 1 ("not at all characteristics of me") to 5 ("very characteristic of me"), higher scores indicate greater uncertainty intolerance
baseline
Positive mental health Scale (PMH)
Time Frame: baseline
Self-report measure assessing emotional and psychological aspects of wellbeing with 9 items rated on a scale from 0 ("do not agree") to 3 ("agree"), score can range from 0 to 27, higher scores indicate greater wellbeing
baseline
Interpersonal Reactivity Index (IRI)
Time Frame: baseline
Self-report measure to assess empathy with 16 Items on a scale from 0 ("never") to 4 ("always"), score can range from 0 to 66, higher scores indicate greater empathy
baseline
State-Trait Anxiety Inventory - Trait (STAI-T)
Time Frame: baseline
Self-report measure of general anxiety with 20 Items (range from 1 = "almost never" to 4 = "nearly always"), Score range from 20 (no anxiety) to 80 (high anxiety)
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christiane A. Melzig, PhD, Philipps University Marburg
  • Principal Investigator: Jana Gessner, M.Sc., Philipps University Marburg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 11, 2023

Primary Completion (Actual)

September 5, 2025

Study Completion (Actual)

September 5, 2025

Study Registration Dates

First Submitted

December 8, 2023

First Submitted That Met QC Criteria

December 25, 2023

First Posted (Actual)

December 27, 2023

Study Record Updates

Last Update Posted (Estimated)

October 2, 2025

Last Update Submitted That Met QC Criteria

September 27, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OMEX_SPIDER

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arachnophobia

Clinical Trials on online psychoeducation video + modeled exposure

Subscribe